Trial register facet
Trial records reported in 2023 — page 2
55 records with a recorded report or completion year of 2023.
Showing 0 records on this page
Records
55 documents · page 2 of 3
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| ORFO-PH2-OBESITY-REGIONAL-CNprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| ORFO-PH2-OBESITY-REGIONAL-JPprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| ORFO-PH2-T2D | Orforglipron | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 383 | 2023 | Moderate |
| ORFO-PH2-T2D-DDIprogramme record | Orforglipron | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| ORFO-PH2-T2D-HEPATIC-IMPprogramme record | Orforglipron | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| ORFO-PH2-T2D-PKprogramme record | Orforglipron | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-OBESITY | Retatrutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 338 | 2023 | Moderate |
| RETA-PH2-OBESITY-DDIprogramme record | Retatrutide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| RETA-PH2-OBESITY-HEPATIC-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-OBESITY-PKprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-OBESITY-RENAL-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D | Retatrutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 281 | 2023 | Moderate |
| RETA-PH2-T2D-DDIprogramme record | Retatrutide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| RETA-PH2-T2D-HEPATIC-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-PKprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-REGIONAL-CNprogramme record | Retatrutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| RETA-PH2-T2D-RENAL-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SELECT | Semaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 17,604 | 2023 | High |
| SELECT-ADHERENCEprogramme record | Semaglutide | Phase 3 | Reported | Observational | — | 2023 | Very low |
| STEP-HFpEF | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 529 | 2023 | Moderate |
| STEP-HFpEF-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| STEP-HFpEF-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-2 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 938 | 2023 | High |
| SURMOUNT-2-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
page 2 of 3